Abatacept in Individuals at High Risk of Rheumatoid Arthritis (APIPPRA): A Randomised, Double-blind, Multicentre, Parallel, Placebo-controlled, Phase 2b Clinical Trial
Lancet doi.org/10.1016/S0140-6736(23)02649-1
Therapeutic intervention during the at-risk phase of RA with abatacept is feasible, with acceptable safety profiles. However, the efficacy of intermittent administration at multiple intervals remains to be assessed.
Investigators aimed to evaluate the feasibility, efficacy, and acceptability of treating high-risk individuals with abatacept.
Keywords:
